Efficacy and Safety of Dabigatran Dual Therapy vs Warfarin Triple Therapy in Atrial Fibrillation After PCI in Relation to Time in Therapeutic Range: A Subgroup Analysis From the RE-DUAL PCI Trial.

被引：0

作者：

Lip, Gregory Y. H. ^{[1
]}

Bhatt, Deepak L. ^{[2
]}

Hohnloser, Stefan H. ^{[3
]}

Kimura, Takeshi ^{[4
]}

Meide, Corinna ^{[5
]}

Nordaby, Matias ^{[6
]}

Oldgren, Jonas ^{[7
,8
]}

Steg, Philippe G. ^{[9
]}

ten Berg, Jurrien M. ^{[10
]}

Cannon, Christopher ^{[11
]}

机构：

[1] Univ Birmingham, Inst Cardiovasc Sci, Birmingham, W Midlands, England

[2] Harvard Med Sch, Brigham & Womens Hosp, Heart & Vasc Ctr, Boston, MA 02115 USA

[3] Goethe Univ Frankfurt, Div Cardiol, Dept Med, Frankfurt, Germany

[4] Kyoto Univ, Dept Cardiovasc Med, Kyoto, Japan

[5] HMS Analyt Software GmbH, Analyt Software, Weimar, Lahn, Germany

[6] Boehringer Ingelheim Int GmbH, TA CardioMetab, Ingelheim, Germany

[7] Uppsala Univ, Uppsala Clin Rsch Ctr, Uppsala, Sweden

[8] Uppsala Univ, Dept Med Sci, Uppsala, Sweden

[9] Hop Bichat Claude Bernard, AP HP, Dept Cardiol, Paris, France

[10] St Antonius Hosp, Cardiol, Nieuwegein, Netherlands

[11] Brigham & Womens Hosp, Test, 75 Francis St, Boston, MA 02115 USA

来源：

CIRCULATION | 2018年 / 138卷

关键词：

Antithrombotic therapy; Atrial fibrillation; Coronary artery disease; Dabigatran; Percutaneous coronary intervention (PCI);

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A11383

引用

页数：3

共 50 条

[21] Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention A Subgroup Analysis From the REDUAL PCI Trial
Berry, Natalia C.
Mauri, Laura
Steg, Philippe Gabriel
Bhatt, Deepak L.
Hohnloser, Stefan H.
Nordaby, Matias
Miede, Corinna
Kimura, Takeshi
Lip, Gregory Y. H.
Oldgren, Jonas
ten Berg, Jurrien M.
Cannon, Christopher P.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2020, 13 (04) : E008349
[22] Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
Cannon, Christopher P.
Bhatt, Deepak L.
Oldgren, Jonas
Lip, Gregory Y. H.
Ellis, Stephen G.
Kimura, Takeshi
Maeng, Michael
Merkely, Bela
Zeymer, Uwe
Gropper, Savion
Nordaby, Matias
Kleine, Eva
Harper, Ruth
Manassie, Jenny
Januzzi, James L.
ten Berg, Jurrien M.
Steg, Gabriel
Hohnloser, Stefan H.
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (16): : 1513 - 1524
[23] Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
Dekkers, Tanja
Lafeber, Melvin
Kramers, Cornelis
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (05): : 484 - 485
[24] Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post-PCI in Patients With Atrial Fibrillation and Diabetes
Maeng, Michael
Steg, Philippe Gabriel
Bhatt, Deepak L.
Hohnloser, Stefan H.
Nordaby, Matias
Miede, Corinna
Kimura, Takeshi
Lip, Gregory Y. H.
Oldgren, Jonas
ten Berg, Jurrien M.
Cannon, Christopher P.
JACC-CARDIOVASCULAR INTERVENTIONS, 2019, 12 (23) : 2346 - 2355
[25] Benefit of Dual versus Triple Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Stenting: Insights From a Landmark Analysis of RE-DUAL PCI
Peterson, Benjamin E.
Bhatt, Deepak L.
Steg, Philippe Gabriel
Oldgren, Jonas
Maeng, Michael
Zeymer, Uwe
Halvorsen, Sigrun
Hohnloser, Stefan H.
Lip, Gregory Y.
Kimura, Takeshi
Nordaby, Matias
Kleine, Eva
ten Berg, Jurrien M.
Cannon, Christopher
CIRCULATION, 2018, 138
[26] Comparison of the Effect of Age (< 75 Versus ≥75) on the Efficacy and Safety of Dual Therapy (Dabigatran plus Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin plus Aspirin plus Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial)
ten Berg, Jurrien M.
Steg, Philippe Gabriel
Bhatt, Deepak L.
Hohnloser, Stefan H.
de Veer, Anne
Nordaby, Matias
Miede, Corinna
Kimura, Takeshi
Lip, Gregory Y. H.
Oldgren, Jonas
Cannon, Christopher P.
AMERICAN JOURNAL OF CARDIOLOGY, 2020, 125 (05): : 735 - 743
[27] Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial
Zeymer, Uwe
Leiva, Orly
Hohnloser, Stefan H.
Steg, Philippe Gabriel
Oldgren, Jonas
Nickenig, Georg
Kiss, Robert Gabor
Ongen, Zeki
Estrada, Jose Navarro
Ophuis, Ton Oude
Lip, Gregory Y. H.
Nordaby, Matias
Miede, Corinna
ten Berg, Jurrien M.
Bhatt, Deepak L.
Cannon, Christopher P.
EUROINTERVENTION, 2021, 17 (06) : 474 - +
[28] Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: Dual or triple approach?
Brunetti, Natale Daniele
Tricarico, Lucia
De Gennaro, Luisa
Correale, Michele
Santoro, Francesco
Ieva, Riccardo
Iacoviello, Massimo
Di Biase, Matteo
IJC HEART & VASCULATURE, 2020, 29
[29] Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting
Cannon, Christopher P.
Gropper, Savion
Bhatt, Deepak L.
Ellis, Stephen G.
Kimura, Takeshi
Lip, Gregory Y. H.
Steg, Ph. Gabriel
ten Berg, Jurrien M.
Manassie, Jenny
Kreuzer, Jorg
Blatchford, Jon
Massaro, Joseph M.
Brueckmann, Martina
Ripoll, Ernesto Ferreiros
Oldgren, Jonas
Hohnloser, Stefan H.
CLINICAL CARDIOLOGY, 2016, 39 (10) : 555 - 564
[30] High body mass index and outcomes of dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor in patients with atrial fibrillation undergoing PCI: Results from RE-DUAL PCI
De Caterina, R.
Lopez Sendon, J. L.
Mehta, S.
Opolski, G.
Oldgren, J.
Steg, P. G.
Hohnloser, S.
Lip, G. Y. H.
Kimura, T.
Nordaby, M.
Kleine, E.
Ten Berg, J. M.
Bhatt, D. L.
Cannon, C.
EUROPEAN HEART JOURNAL, 2018, 39 : 458 - 458

← 1 2 3 4 5 →